ArticleCurrent oncology reports2025
Complementary Chinese Herbal Medicine Use and Gastrointestinal Cancers: A Scoping Review of Usage Patterns and Survival Outcomes in Taiwanese Population-Based Studies.
Article in Current oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundGastrointestinal (GI) cancers remain a significant global health burden with high mortality rates. Chinese herbal medicine (CHM) has emerged as a complementary therapy, yet limited real-world evidence regarding its use and effectiveness in GI cancers.
methodsThis scoping review evaluated findings on CHM usage patterns and survival outcomes in GI cancer patients from studies using the Taiwan National Health Insurance Research Database, a uniquely data source covering 99.99% of the Taiwanese population. Five databases were searched for studies from January 1, 1997, to November 30, 2024. Information on exposures and outcomes were extracted, alongside study designs, patient characteristics, methodologies, and results.
resultsWe identified seven studies focusing on liver (n = 3), gastric (n = 2), pancreatic (n = 1) and colon (n = 1) cancers. Of the 6 studies that evaluated usage patterns, Bai-Hua-She-She-Cao (Oldenlandia Diffusae Herba) and Dan-Shen (Salviae Miltiorrhizae Radix et Rhizoma) were the most frequently used herbs among Taiwanese GI cancer patients. Of the 6 studies that investigated survival, complementary CHM use was associated with lower mortality (adjusted HRs = 0.41-0.68) compared to conventional treatment only. Subgroup analyses showed longer durations of CHM use were associated with greater survival benefits. However, potential for confounding and bias tempers any conclusions.
conclusionThis review underscores the potential role of CHM as a complementary treatment for improving survival in GI cancers in real-world settings. These findings will require future rigorously-designed multinational observational studies and trials to further identify the role of specific herbal treatment in contemporary oncological care to improve outcomes for people with GI cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.